Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.74 |
| ▸ | HTR1B | P28222 | 10/20 | 0.74 |
| ▸ | HTR1A | P08908 | 7/20 | 0.74 |
| ▸ | HTR2A | P28223 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | HTR1F | P30939 | 2/20 | 0.57 |
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MPO | P05164 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739219 | 1.00 | HTR1D (0.74) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Fumaric Acid SCHEMBL7813643 | 0.92 | HTR1B (0.65) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Fumaric Acid SCHEMBL7813640 | 0.92 | HTR1B (0.65) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Maleic Acid SCHEMBL7813633 | 0.92 | HTR1B (0.65) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL2617889 | 0.88 | HTR1D (0.78) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL7811321 | 0.86 | HTR1D (0.75) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL8091337 | 0.86 | HTR1D (0.75) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL5528416 | 0.86 | HTR1D (0.75) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL7811586 | 0.86 | HTR1D (0.75) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL8091339 | 0.86 | HTR1D (0.75) | HTR1DHTR1BHTR1AHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0636623-B1 | Indole derivatives as 5-HT1- like agonists | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | claimed |
| EP-4681714-A2 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4048249-B1 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MAPLIGHT THERAPEUTICS INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240189240-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | MAPLIGHT THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-117750957-A | Pharmaceutical composition comprising zolmitriptan | 地图之光治疗股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4313037-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | MapLight Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220387396-A1 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MAPLIGHT THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022204399-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | MAPLIGHT THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4048249-A1 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114901270-A | Methods of treating symptoms of autism spectrum disorders | 地图之光治疗股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189240-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | HTR3A, HTR5A, GRIN3A | HTR1D 9/4885HTR1B 13/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.